PubRank

P Randhawa

Author PubWeight™ 85.13‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008 8.09
2 Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 5.39
3 Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014 3.43
4 Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010 3.29
5 Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006 2.48
6 A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant 2010 2.14
7 A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995 2.09
8 Experience with liver and kidney allografts from non-heart-beating donors. Transplantation 1995 1.83
9 BK polyomavirus in solid organ transplantation. Am J Transplant 2013 1.83
10 "Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant 2013 1.52
11 An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant 2001 1.48
12 Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000 1.44
13 Pulmonary blastoma. An immunohistochemical analysis with comparison with fetal lung in its pseudoglandular stage. Am J Clin Pathol 1990 1.41
14 FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 1991 1.37
15 BK virus in solid organ transplant recipients. Am J Transplant 2009 1.32
16 BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995 1.28
17 Development and experience with an integrated system for transplantation telepathology. Hum Pathol 2001 1.23
18 A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. Clin Transplant 1994 1.15
19 A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999 1.14
20 A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc 1995 1.13
21 Tacrolimus in renal transplantation. Transplant Proc 1996 1.10
22 Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation. Am J Kidney Dis 2001 1.07
23 Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant 2008 1.05
24 Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum Pathol 1989 0.99
25 Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2008 0.98
26 Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999 0.96
27 Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation 1997 0.95
28 Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011 0.91
29 Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 1998 0.91
30 The Banff 2009 Working Proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome. Am J Transplant 2012 0.91
31 Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002 0.91
32 Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: does dissynchronous rejection really exist? Transplantation 2000 0.91
33 Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004 0.91
34 European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clin Microbiol Infect 2014 0.90
35 Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005 0.88
36 Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001 0.88
37 Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2011 0.88
38 Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients. Hum Pathol 1996 0.85
39 Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts. Am J Transplant 2014 0.84
40 Arcuate and interlobular phlebitis in renal allografts. Hum Pathol 2001 0.83
41 Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation 1999 0.82
42 Banff initiative for quality assurance in transplantation (BIFQUIT): reproducibility of C4d immunohistochemistry in kidney allografts. Am J Transplant 2013 0.82
43 "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation 1996 0.82
44 Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. Transplantation 1994 0.82
45 Biologic diversity of polyomavirus BK genomic sequences: Implications for molecular diagnostic laboratories. J Med Virol 2008 0.82
46 Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc 1998 0.81
47 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection. Clin Transpl 2010 0.81
48 Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993 0.80
49 Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc 1997 0.79
50 HLA susceptibility to BKV infection. Am J Transplant 2006 0.79
51 Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant 1997 0.79
52 Precision diagnostics in transplantation: from bench to bedside. Am J Transplant 2012 0.78
53 Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. Transplant Proc 1999 0.78
54 The "borderline" renal allograft biopsy in the era of molecular diagnostics: a sampling conundrum? Am J Transplant 2011 0.78
55 Dexamethasone increases superoxide dismutase activity in serum-free rat fetal lung organ cultures. Pediatr Res 1986 0.78
56 Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl 1994 0.78
57 Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996 0.77
58 FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 1993 0.77
59 Candida albicans osteomyelitis in a liver transplant recipient: a case report and review of the literature. Transplantation 1996 0.76
60 Kidney transplantation with bone marrow augmentation: five-year outcomes. Transplant Proc 2001 0.76
61 IVIG rescue therapy in renal transplantation. Transplant Proc 2001 0.76
62 Epstein-Barr virus-encoded RNA expression as a risk factor for the development of posttransplantation lymphoproliferative disease. Hepatology 1995 0.75
63 High-risk donors: expanding donor criteria. Transplant Proc 1999 0.75
64 Cortical scarring as a variable in the assessment of donor kidney biopsy specimens. Transplantation 2001 0.75
65 Incorporation of pathology and laboratory findings into management algorithms for polyomavirus nephropathy. Am J Transplant 2013 0.75
66 A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc 2002 0.75
67 Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc 1997 0.75
68 Assigning renal allograft demise to antibodies: are we underplaying the role of T cells? Am J Transplant 2012 0.75
69 Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc 1996 0.75
70 A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol 1998 0.75
71 A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc 1999 0.75
72 Fibrous dysplasia of the nasal bone: case reports and literature review. J Laryngol Otol 2013 0.75
73 Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. Transplant Proc 2000 0.75
74 The pathology of lung transplantation. Pathol Annu 1992 0.75
75 Renal cortical neoplasms in long term survivors of solid organ transplantation. Transplantation 2000 0.75
76 Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clin Transpl 1999 0.75
77 Co-administration of co-trimoxazole does not augment tacrolimus-induced impairment in kidney function in rats. Ren Fail 1999 0.75
78 Outcome of kidney transplantation under tacrolimus-based immunosuppression in elderly patients. J Transpl Coord 1999 0.75
79 Severe acute T cell and antibody-mediated rejection in ectopic kidney allografts with or without mouse polyomavirus infection. Am J Transplant 2012 0.75